<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03430830</url>
  </required_header>
  <id_info>
    <org_study_id>ASC-ASC16-I-CTP-03</org_study_id>
    <nct_id>NCT03430830</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China</brief_title>
  <official_title>A Randomized, Open, Three-dose (100 mg, 200 mg and 300 mg) Duplicate Bifunctional Crossover and Fixed 200mg Continuous Dose Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascletis Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascletis Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics and safety of ASC16 after
      3-single dose(50mg、100mg、200mg) or fixed continuous dose(200mg) in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2018</start_date>
  <completion_date type="Anticipated">March 15, 2018</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak plasma concentration (Cmax)</measure>
    <time_frame>27 days</time_frame>
    <description>Pharmacokinetics (blood draws, pre- and post-dose)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>27 days</time_frame>
    <description>Pharmacokinetics (blood draws, pre- and post-dose)</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Chronic Hepatitis c</condition>
  <arm_group>
    <arm_group_label>GROUP 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st day: 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: 1 tablet of Ravidasvir 200mg administered orally once daily; 3rd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily ; 19th to 25th day： Ravidasvir 200mg administered orally once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GROUP 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st day: Ravidasvir 200mg administered orally once daily; 2nd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily ; 3rd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GROUP 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 3rd day: Ravidasvir 200mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GROUP 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: Ravidasvir 200mg administered orally once daily; 3rd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GROUP 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st day: Ravidasvir 200mg administered orally once daily; 2nd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 3rd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GROUP 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1st day: 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 3rd day: Ravidasvir 200mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ravidasvir 50mg</intervention_name>
    <description>50mg, Tablet</description>
    <arm_group_label>GROUP 1</arm_group_label>
    <arm_group_label>GROUP 2</arm_group_label>
    <arm_group_label>GROUP 3</arm_group_label>
    <arm_group_label>GROUP 4</arm_group_label>
    <arm_group_label>GROUP 5</arm_group_label>
    <arm_group_label>GROUP 6</arm_group_label>
    <other_name>ASC16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ravidasvir 200mg</intervention_name>
    <description>200mg, Tablet</description>
    <arm_group_label>GROUP 1</arm_group_label>
    <arm_group_label>GROUP 2</arm_group_label>
    <arm_group_label>GROUP 3</arm_group_label>
    <arm_group_label>GROUP 4</arm_group_label>
    <arm_group_label>GROUP 5</arm_group_label>
    <arm_group_label>GROUP 6</arm_group_label>
    <other_name>ASC16</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18-45 years old;

          -  Male body weight not less than 50kg; Female body weight not less than 45kg; BMI in the
             range of 19~24kg/m2

          -  Healthy men or women based on history, physical examination, laboratory examination
             and ECG.

          -  no plan of pregnancy in at least six months, and willing to take effective measures to
             prevent contraception from the first time when the drug is administered till the last
             time the drug is administered within 30 days.

          -  Female has negative pregnancy tests at the screening stage.

          -  Voluntary to sign the informed consent.

        Exclusion Criteria:

          -  Have medical history, or has disease, such as cardiovascular system, respiratory
             system, endocrine and metabolic system, urinary system, digestive system, blood
             system, nerve system disease or psychiatric disease and acute or chronic infectious
             diseases and malignant tumors.

          -  Has a history of drug or food allergy.

          -  Positive hepatitis A antibody，positive hepatitis B surface antigen， positive hepatitis
             C antibody，syphilis antibody or HIV antibody at screening.

          -  Laboratory tests out of normal range and judged by the investigators as clinically
             significant.

          -  Had gastrointestinal surgery, vagotomy, intestinal resection or any possible
             interference with gastrointestinal peristalsis, pH or absorbed by surgery.

          -  Pregnant, lactating women and people who unwilling to take effective measures to
             prevent contraception.

          -  People who consumed pomelo, apple or orange and foods or drinks containing their
             extracted ingredients within 3 days of taking the drug.

          -  Any prescription or over-the-counter medications, herbs, and vitamins are required to
             be taken prior to or within the first month of taking the drug.

          -  Selected within the first 6 months of smoking, alcohol, drug abuse or history of drug
             abuse.

          -  Selected within the first 3 months had blood loss or blood donation of 200ml.

          -  Participate in other clinical trials within the first 3 months of the study and
             received other study drug treatment.

          -  In addition to the above, the investigators judged not suitable for participating in
             this clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yahong Chen, Master</last_name>
    <role>Study Director</role>
    <affiliation>Ascletis Pharmaceuticals Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yicheng Zhao, Master</last_name>
    <phone>+86057185389732</phone>
    <email>yicheng.zhao@ascletis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yahong Chen, Master</last_name>
    <phone>+86057185389732</phone>
    <email>yahong.chen@ascletis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Hospital of Zhejiang Province</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianzhong Shen, Doctor</last_name>
      <phone>+8687236560</phone>
      <email>stjz@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2018</study_first_submitted>
  <study_first_submitted_qc>February 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2018</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

